Nam Nguyen-Hoang

Nam Nguyen-Hoang

Auto-generated profile, based on publicly available information

Nam Nguyen-Hoang

University of Michigan–Ann Arbor 2 Ann Arbor

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2021 in JAC-Antimicrobial Resistance
Verified
Journal Article
Open access
PDF file
NNNam Nguyen-Hoang
Nam Nguyen-Hoang
QBQuynh Thi Huong Bui
Quynh Thi Huong Bui
To assess the appropriateness of empirical antimicrobial therapy for sepsis and septic shock and determine factors associated with patient treatment outcomes at a Vietnamese national hospital. A cross-sectional study was conducted on 134 patients diagnosed with sepsis and/or septic shock at Thong-Nhat Hospital, Ho Chi Minh City, Vietnam, from January 2018 to June 2018. Appropriateness of antimicrobial therapy was defined as physician adherence to antimicrobial guidelines using the Sanford Guide to Antimicrobial Therapy and the Vietnam national guidelines. Bayesian model averaging technique was used to identify the related factors associated with patient treatment outcomes. The median age of patients was 70 years. Organisms were identified in 54.5% of cases and predominated by Escherichia coli and staphylococci. Appropriate empirical antimicrobial agents were initiated in 56.6% (n = 73) of all cases. Of these patients, 31 cases (42.5%) and 61 cases (83.6%) received the antimicrobials in accordance with recommendations related to dosage and route of administration, respectively, bringing the overall rate of appropriate empirical antimicrobial therapy down to 23.3%. Patients who progressed to septic shock, received inappropriate antimicrobial therapy and required ICU admission were more likely to suffer treatment failure. The study findings suggest that clinicians should appropriately adhere to antimicrobial guidelines, especially in patients with septic shock and those who require ICU care, to improve treatment outcomes.

2 April 2025 in EBioMedicine
Verified
Journal Article
Open access
WZWenbo Zhang
Wenbo Zhang
NNNam Nguyen-Hoang
Nam Nguyen-Hoang
SRSean C.S. Rivrud
Sean C.S. Rivrud
AZAnne-Fleur Zandbergen
Anne-Fleur Zandbergen
YYYalan Yan
Yalan Yan
Harold SniederHarold Snieder
Harold Snieder
Critical illness is complex, and genetic research holds the potential to uncover underlying disease mechanisms. However, existing research results have not been systematically summarized. This study aims to compile all genetic association studies in critically ill patients and assess their risks of bias. We systematically reviewed PubMed, EMBASE, and the Cochrane Library (PROSPERO protocol: CRD42021209744) and conducted a bias risk assessment of identified studies using a newly developed risk-of-bias assessment tool for genetic association studies. We compiled all significant single nucleotide polymorphisms (SNPs) from the studies identified in our systematic review and conducted a lookup in the results of two genome-wide association studies (GWASs) in critically ill patients. We identified a total of 61 studies that evaluated genetic variants with various traits in adult intensive care patients, encompassing a total of 126 genetic loci and focussing on six clustered critical care-related traits. Assessment of the risk of bias across these studies revealed that 97% of the studies demonstrated some concerns or high risk of bias and only two studies (3%, both GWAS), had an overall low risk of bias. Only two significantly associated SNPs emerged from the two studies assessed to have a low risk of bias. One SNP (rs4957796) in FER was associated with 28-day survival (p = 3.4 × 10-9) and mortality (p = 5.6 × 10-8), and rs9508032 in FLT1 was associated with respiratory failure (p = 5.2 × 10-8). Fifty-four significant associations were replicated in the candidate gene studies, but most had an overall high risk of bias. Only one association, of rs2569190 in CD14 with mortality, remained significant after multiple testing correction. Our systematic review underscored a deficiency in high-quality genetic research in critical care medicine. The detected gaps emphasize an urgent need for additional rigorous genetic association studies that are preferably genome-wide, to enhance our understanding of the underlying mechanisms of critical illness. Wenbo Zhang was financially supported by a grant from the China Scholarship Council (File no. 202006210041). Carlos Flores was funded by Instituto de Salud Carlos III (PI23/00980 and CB06/06/1088) and co-financed by the European Regional Development Fund, "A way of making Europe" from the European Union; and the agreement OA23/043 with Instituto Tecnológico y de Energías Renovables (ITER) to strengthen scientific and technological education, training, research, development and scientific innovation in genomics, epidemiological surveillance based on massive sequencing, personalized medicine, and biotechnology. Eva Suarez-Pajes was financially supported by Agencia Canaria de Investigación, Innovación y Sociedad de la Información de la Consejería de Economía, Conocimiento y Empleo y por el Fondo Social Europeo (FSE) Programa Operativo Integrado de Canarias 2014-2020, Eje 3 Tema Prioritario 74 (85%) (TESIS2022010042).

1 January 2025 in JCO Precision Oncology
Verified
Journal Article
Closed access
NNNam Nguyen-Hoang
Nam Nguyen-Hoang
YLYaping Liu
Yaping Liu
NHN. Lynn Henry
N. Lynn Henry
MPManjunath Pai
Manjunath Pai
HZHao-Jie Zhu
Hao-Jie Zhu
DHDaniel Hertz
Daniel Hertz
PURPOSE: Taxane-induced peripheral neuropathy (TIPN) is a dose-limiting toxicity of paclitaxel in patients with cancer. TIPN prediction is challenging although patients with higher systemic paclitaxel exposure have higher TIPN risk. This study aimed to identify protein predictors of TIPN and paclitaxel pharmacokinetics (PK). METHODS: This is a retrospective analysis of a prospective study of females with early-stage breast cancer receiving weekly paclitaxel. TIPN was assessed using the sensory subscale of the European Organisation for Research and Treatment of Cancer QLQ-Chemotherapy-Induced Peripheral Neuropathy (CIPN)20 (CIPN8). A blood sample was collected within 10 minutes before the end of the first paclitaxel infusion to measure plasma proteins using liquid chromatography-mass spectrometry and to estimate maximum systemic paclitaxel concentration ( C max ). A second sample was collected approximately 24 hours after the first infusion to estimate paclitaxel time above threshold ( T c >0.05 ). Linear mixed-effect and regression models were used to identify proteins predictive of TIPN and paclitaxel PK parameters, respectively, using a Bonferroni-adjusted α = .0006. RESULTS: Data from 36 participants were included in the analysis testing associations of 83 proteins with TIPN or PK. Higher levels of complement C3 were associated with more severe TIPN trajectories ( P = .0002). No proteins were associated with either C max or T c >0.05 (all P > .0006). CONCLUSION: Complement C3 concentration at the end of initial paclitaxel infusion may be useful for identifying patients with breast cancer and potentially other tumor types who could benefit from TIPN prevention strategies to improve long-term treatment outcomes.

27 February 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
NNNam Nguyen-Hoang
Nam Nguyen-Hoang
KNKelly Nugent
Kelly Nugent
SJSophia Jaso
Sophia Jaso
FSFaisal Shakeel
Faisal Shakeel
JKJung Won Kwon
Jung Won Kwon
DHDaniel Hertz
Daniel Hertz
Purpose: Fluoropyrimidine (FP) chemotherapy can cause life-threatening toxicity. Four DPYD polymorphisms (DPYD*2A, *13, p.Asp949Val, HapB3) are well-established to increase FP toxicity risk. This study aimed to identify additional DPYD polymorphisms that increase FP toxicity. Experimental Design: Adult patients treated with standard doses of systemic FP (5-fluorouracil/capecitabine) for any cancer with available DPYD genetic data were included. The primary endpoint was a composite of CTCAE grade ≥3 toxicity or treatment modification due to toxicity in the first two FP cycles. A literature-curated list of suspected deleterious unvalidated DPYD variants was classified as uncommon (minor allele frequency <0.01) or common. The genetic association with toxicity was analyzed via multivariable logistic regression. Results: Among 849 eligible patients, the composite toxicity endpoint occurred in 25%. Genetic data were available for five uncommon and six common suspected deleterious DPYD variants. In the primary analysis of 799 patients who did not carry a validated variant, carriers of uncommon deleterious variants (1.1% of patients) had significantly higher toxicity risk than non-carriers (67% vs. 24%; adjusted OR 7.36; 95% CI 1.75–38.20; p = 0.009). None of the common deleterious variants were associated with toxicity. Toxicity prediction in the entire cohort (n = 849) was slightly improved by testing the uncommon and validated variants vs. testing only the validated variants (positive predictive value: 44.1% vs. 40.0%). Conclusions: Five uncommon DPYD variants, in combination, increase FP toxicity risk and improve risk prediction. Testing these variants could identify more high-risk patients who should receive adjusted FP doses to prevent severe toxicity.

3 August 2026
Verified
Other
Open access
NNNam Nguyen-Hoang
Nam Nguyen-Hoang
KNKelly Nugent
Kelly Nugent
SJSophia Jaso
Sophia Jaso
FSFaisal Shakeel
Faisal Shakeel
JKJung Won Kwon
Jung Won Kwon
DHDaniel Hertz
Daniel Hertz
Supplemental Table S1 from Identification of Additional DPYD Polymorphisms That Increase the Risk of Severe Fluoropyrimidine Toxicity and Improve Predictive Accuracy when Combined with Previously Validated Variants

3 August 2026
Verified
Other
Open access
NNNam Nguyen-Hoang
Nam Nguyen-Hoang
KNKelly Nugent
Kelly Nugent
SJSophia Jaso
Sophia Jaso
FSFaisal Shakeel
Faisal Shakeel
JKJung Won Kwon
Jung Won Kwon
DHDaniel Hertz
Daniel Hertz
Purpose:Fluoropyrimidine (FP) chemotherapy can cause life-threatening toxicity. Four DPYD polymorphisms (DPYD*2A, *13, p.Asp949Val, and HapB3) are most well established to increase FP toxicity risk. This study aimed to identify additional DPYD polymorphisms that increase FP severe toxicity. Experimental Design:Adult patients treated with standard doses of systemic FP (5-fluorouracil/capecitabine) for any tumor type with available genetic data were included. The primary toxicity endpoint was a composite of Common Terminology Criteria for Adverse Event grade ≥3 toxicity or treatment modification due to toxicity in the first two FP cycles. A literature-curated list of suspected deleterious unvalidated DPYD variants was classified as uncommon (minor allele frequency <0.01) or common. The genetic association with toxicity was analyzed via multivariable logistic regression. Results:Among 849 eligible patients, the composite toxicity endpoint occurred in 25%. Genetic data were available for five uncommon and six common suspected deleterious DPYD variants. In the primary analysis of 799 patients who did not carry a validated variant, carriers of an uncommon deleterious variant (1.1% of patients) had significantly higher risk of toxicity than noncarriers (67% vs. 24%; adjusted OR, 7.36; 95% confidence interval, 1.75–38.20; P = 0.009). None of the common deleterious variants were associated with toxicity. Toxicity prediction in the entire cohort (n = 849) was slightly improved by testing the uncommon and validated variants versus testing only the validated variants (positive predictive value: 44.1% vs. 40%). Conclusions:Five uncommon DPYD variants, in combination, increase FP toxicity risk and improve risk prediction. Testing these variants could identify more high-risk patients who should receive adjusted FP doses to prevent severe toxicity.See related commentary by Gaddy et al., p. 3109